As employer health costs climb, reduced coverage for weight loss drugs will expand the self-pay GLP-1 market and intensify price competition among drugmakers.

Consumers budget for weight loss as they cut spending elsewhere. Gyms, drugmakers, and supplement brands can build on that commitment with services supporting long-term health goals.

Novo's Wegovy pill gains failed to offset declines in injectable sales. Investors continue to favor companies like Lilly with broader drug pipelines despite a positive outlook for GLP-1 pills.

An experimental heart drug missed a key clinical trial result, delivering a blow to Novo Nordisk as it looks to expand beyond GLP-1s.

Ad watchdog sides with pharma over misleading GLP-1 microdose telehealth marketing—but this scrutiny won't impact sales thanks to high consumer demand.

Nourish's fresh capital fuels its model that combines GLP-1 drugs with health coaching—an emerging trend as insurers and employers demand proof that digital care reduces wasteful spending.

Pharma execs detail strategies for gov’t pricing deals, countering vaccine skepticism, and driving D2C sales at FT’s US Pharma and Biotech Summit.

Unless Congress codifies drug pricing deals, TrumpRx risks serving more as political optics than a driver of meaningful patient affordability.

Amazon aims to turn GLP-1 demand into a funnel for One Medical, though limiting new prescriptions to members softens the competitive threat to other telehealth players.

The offering lets employers subsidize employees’ cash-pay price—sidestepping opaque PBM rebates and helping rein in rising pharmacy costs.

But as competition intensifies, high traffic isn’t enough—brands must pair visibility with proven product efficacy to convert surging consumer interest into loyalty.

Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.

AI’s growing clout in healthcare and pharma and candid confessions from drugmaker CEOs dominated the narrative at JPM 2026.

Novo and Lilly prohibit telehealth partners from offering compounded GLP-1s, eroding compounders’ ability to distribute.

News on drugmaker deals, weight loss drug coverage, medication price hikes, and health insurance to kick off the New Year.

As more Americans take weight loss drugs, eating, shopping, and healthcare expectations are all evolving

35 state attorneys general are pushing Meta for tighter enforcement of its advertising policies amid a “surge of misleading marketing for weight loss products” on Facebook and Instagram. The state AGs’ letter will surely get the attention of the FDA, meaning telehealth marketers must ensure they aren’t specifically promoting GLP-1s to people who don’t meet the clinical criteria or using messaging that body shames. Meanwhile, social media companies and advertising platforms need to strictly enforce transparency disclosures on AI-generated ads while closely reviewing all weight loss drug promotions, given the risks of misleading claims and unrealistic expectations.

Hims & Hers is officially bringing its subscription weight loss program to the UK. But rising prices of some GLP-1 medications in the UK may lower the incentive for consumers to sign up for a membership with a telehealth company offering prescriptions.

Structure Therapeutics’ experimental obesity pill led to an average 12.1% weight loss after 36 weeks on a 120 mg daily dose, which stacks up well against competitors. Newcomers to the weight loss drug market still face key disadvantages, even with strong trial results. For smaller weight loss drug developers that may not have the risk appetite or resources to compete with larger players, the best way to cash in on a market dominated by two giants may be to pursue a partnership or acquisition.

Households with GLP-1 users could account for 35% of food and beverage sales by 2030, up from 23% today, per Circana. Rising GLP-1 usage is reshaping grocery spending, with profound implications for foodmakers and grocers. As GLP-1s grow more accessible—thanks to microdosing, efforts to make the drugs more affordable, and the pending release of a weight-loss pill—their impact will be more deeply felt beyond food to sectors including apparel, wellness, beauty, and restaurants.